Pharmacodynamics Services
KCAS Bio provides pharmacodynamics services (PD) across preclinical and clinical development. Services focus on measuring the biological effects of a drug at its target, enabling evidence-based decisions on efficacy, safety, and dose selection.
Your bioanalytical partner for PD assays
Context-of-Use Driven Strategy
PD assay design and validation are guided by the drug’s mechanism of action, the intended application of the data, and the regulatory context. Whether supporting target engagement, efficacy endpoints, or safety assessments, we ensure methods are scientifically and regulatorily fit-for-purpose.
Broad Analytical Platform Suite
We leverage LBA platforms, hybrid LC-MS/MS, flow cytometry, ELISpot, and qPCR/ddPCR to measure pharmacodynamic endpoints across a wide range of sample types and matrices.
Biomarker-Integrated PD Strategy
PD endpoints are often biomarkers by nature. Our teams integrate biomarker expertise into every PD program, aligning assay strategies with soluble and cellular endpoints to generate coherent, decision-enabling datasets.
Regulatory Alignment
All workflows can be executed under GLP, non-GLP, or GxP compliance, with documentation aligned to FDA, EMA, and ICH M10 guidance for bioanalytical PD data.
What is PD analysis?
PD analysis measures how a drug affects the body: its biological and physiological effects at the site of action. Understanding a therapeutic’s PD profile is essential to establish target engagement, demonstrate proof of mechanism, and support dose selection.
KCAS Bio supports PD programs with comprehensive bioanalytical services enabling measurement of pharmacodynamic endpoints for all drug modalities, at any stage of development, to guide sponsor decision‑making.
Our PD services include:
- PD biomarker assay development and validation
- Target engagement and receptor occupancy assays
- Efficacy and safety endpoint quantification
- Preclinical and clinical PD sample analysis
- Regulated and non-regulated sample analysis and reporting
PD studies are frequently conducted alongside PK analysis to establish exposure-response relationships.
Your molecule, our expertise. Let KCAS Bio help with your PD studies.
Applications of PD analysis in drug development
PD analysis is applicable across therapeutic modalities and disease areas, with specific uses and requirements at each stage of drug development, from early discovery through clinical studies.
Discovery: Early characterization of a drug’s mechanism of action, including target binding and downstream signaling effects, to prioritize and differentiate candidates.
Preclinical Studies: Measurement of pharmacodynamic endpoints in animal models under GLP or non-GLP conditions to establish proof of mechanism, assess dose-response relationships, and identify early efficacy and safety signals.
Pre-IND Preparation: Development and validation of fit-for-purpose PD assays, including full, partial, or cross-validation as needed, to ensure robust methods are ready for clinical sample testing.
Clinical Development: Implementation of validated PD bioanalytical assays to measure target engagement, downstream biological effects, and clinical efficacy endpoints, generating regulatory-compliant data from Phase I through late-stage trials.
Capabilities and tools for PD analysis
KCAS Bio leverages advanced analytical platforms to deliver precise, reliable PD data. Whether your program requires quantification of soluble mediators, immune cell profiling, or gene expression analysis, we select the most appropriate technology and assay design based on your project’s context-of-use.
Ligand Binding Assays
LBAs are a cornerstone of PD biomarker analysis, offering high sensitivity and specificity for quantifying cytokines, growth factors, receptor proteins, and other soluble PD endpoints in complex biological matrices. They are well-suited for both preclinical and clinical PD monitoring and are widely used to assess target engagement and downstream effector responses.
Hybrid LC–MS/MS
Hybrid LC–MS/MS enables precise quantification of PD endpoints requiring structural specificity beyond what immunoassays can provide. It is particularly suited for small molecule target engagement, enzyme activity measurements, lipid mediators and metabolites, and protein biomarkers where isoform discrimination or detection of post-translational modifications is essential.
Flow Cytometry
Flow cytometry enables multi-parameter characterization of immune cell populations, receptor occupancy, and functional cellular endpoints at the single-cell level. It is particularly valuable for PD programs involving immunomodulatory therapies, cell & gene therapies, and oncology, where cellular response profiles are key efficacy readouts.
Molecular Services
Molecular techniques including qPCR and ddPCR support PD programs requiring gene expression analysis, transcript quantification, and nucleic acid-based biomarker measurement. Capabilities include:
- mRNA expression of target genes and downstream pathways
- microRNA and small RNA quantification
- Cell persistence and engraftment measurements for cell & gene therapies
- Copy number analysis for transgene expression
ELISpot
ELISpot provides high-sensitivity detection of cytokine secretion at the single-cell level, making it a powerful tool for PD studies requiring quantification of antigen-specific immune responses, including T cell and B cell functional activity.
Technology and instrumentation for PD analysis
Our laboratories are equipped with state-of-the-art instrumentation to provide reliable results for PD analysis.
We have advanced technology to move your science forward. Speak with a KCAS Bio expert now.
Why work with KCAS Bio?
Full-Service Bioanalysis
End-to-end method development, validation, and reporting under one roof.
Regulatory Expertise
Deep familiarity with ICH, FDA, and EMA requirements.
Cutting-Edge Technology
Cutting-edge technologies for sensitive, reliable PD analysis across LBA, Hybrid LC-MS/MS and molecular biology assays.
Flexible, Customized Workflows
Tailored workflows to meet unique project goals and timelines.
Broad Sample Type and Matrix Expertise
Plasma, serum, urine, CSF, and tissues plus unstable/rare matrices and microsampling methods.
Global Presence with Harmonized Quality
Consistent technical standards and harmonized operations worldwide.
PD analysis services FAQs
What is the difference between PK and PD analysis?
PK analysis measures drug concentrations in the body over time : what the body does to the drug. PD analysis measures the biological effects of the drug at its target : what the drug does to the body. Both are frequently studied in parallel, as PK/PD relationships are central to understanding exposure-response and informing optimal dosing.
Do you offer GLP and non-GLP OD analysis?
PD bioanalysis can be conducted under GLP or non-GLP compliance, depending on study objectives and development stage, with appropriate documentation to support regulatory submissions when required.
Do you support PK bioanalysis across all drug modalities?
Yes. PD bioanalytical services support a wide range of modalities, including small molecules, monoclonal antibodies, bispecifics, antibody-drug conjugates (ADCs), cell therapies, and nucleic acid and gene-based therapies.
Which approach do you choose for PD analysis?
The choice of approach depends on the nature of the PD endpoint and the mechanism of action of the drug. Soluble PD endpoints (such as cytokines, growth factors, and receptor proteins) are measured in biological fluids using LBA platforms or hybrid LC-MS/MS. Cellular PD endpoints (such as immune cell activation, receptor occupancy, or functional T cell responses) are measured using flow cytometry or ELISpot. When structural specificity or metabolite quantification is required, hybrid LC-MS/MS is the preferred approach. Our experts can advise on the most appropriate platform based on your program’s context-of-use.
What validation approach applies to PD assays?
PD assay validation follows a fit-for-purpose framework, as described in FDA and EMA bioanalytical guidelines and ICH M10. The rigor of validation is calibrated to the context-of-use of the assay, whether it is exploratory, used for patient stratification, or intended to support a regulatory submission.
Additional resources
webinars
As the field of biotherapeutics rapidly evolves, the development of advanced conjugated therapies such as Antibody-Drug Conjugates (ADCs), Antibody-RNA Conjugates (ARCs), siRNA/oligos, and antibody-peptide conjugates has gained significant momentum. These next-generation therapeutics offer promising efficacy and safety profiles for treating various conditions, including cancer, rare diseases, and in vaccine…
Blogs
Understanding the intricate relationship between drugs and the human body is crucial for effective medical treatments. Two fundamental concepts in pharmacology – pharmacokinetics and pharmacodynamics – play pivotal roles in this understanding. This blog post will delve into these concepts, exploring their differences and significance in drug development and…
Blogs
Pharmacodynamics (PD) is defined as the study of the biochemical and physiological effects of drugs and the mechanisms of their actions. Where pharmacokinetics looks at how the organism processes the drug, pharmacodynamics studies…
Tell us how we can help with your project
We've earned our reputation for delivering reliable, error-free data. We understand the importance of speed, flexibility, and consistency and only make promises we can keep.